Cancer antigens and utilization thereof

a cancer antigen and human cancer technology, applied in the field of human cancer antigens, can solve the problems of large number of advanced cancers that have not yet been treated, lack of anti-tumor effects, and difficulty in identifying tumor antigens from carcinomas other than melanomas

Inactive Publication Date: 2006-11-09
MEDINET CO LTD
View PDF4 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024] In another aspect, the present invention provides an agent for preventing and/or treating cancers, which comprises the aforementioned cancer an

Problems solved by technology

However, a large number of advanced cancers have not yet been treated under the present circumstances.
However, sufficient antitumor effects have not yet been exhibited.
Thus, it is difficult to isolate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer antigens and utilization thereof
  • Cancer antigens and utilization thereof
  • Cancer antigens and utilization thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0088] The serum was collected from a patient with pancreatic cancer. The collected serum was conserved at −80° C. From this serum sample, an antibody reacting with Escherichia coli and λ phage was eliminated by using a column that was filled with dissolved matter of Escherichia coli and phage and sepharose 4B. Thereafter, the resultant serum was 100 to 800 times diluted and then used.

[0089] A phage cDNA library produced by inserting cDNA of a pancreatic cancer cell line CFPAC-1 into a λZAP express vector was purchased from Stratagene, La Jolla, Calif. Escherichia coli was infected with this λ phage cDNA library, and it was then cultured on NZY plate medium at 42° C. for 6 hours, so as to produce plaques. Thereafter, the plate was covered with a nitrocellulose membrane into which isopropyl β-D-thiogalactoside (IPTG) had been infiltrated at 37° C. for 3 hours, so as to produce a protein encoded by the cDNA that had been incorporated into λ phage in the plaques.

[0090] The protein pr...

example 2

[0094] A motif binding to HLA-A24, for which 60% of Japanese people get positive, is identical to a motif, to which Kd of a BALB / c mouse binds. A peptide that is shared by human hsp105 and mouse hsp105 and is predicted to bind to both HLA-A24 and Kd is selected from the sequence of hsp105, using HLA-peptide binding prediction (http: / / bimas / dcrt.nih.gov / molbio / hla_bind / ). Nine types of peptides consisting of 9 or 10 amino acids were synthesized by the Fmoc / PyBOP method. The sequences of the peptides and the estimated binding values to Kd are shown in Table 2.

TABLE 2hsp105-derived peptideshsp105-derived peptidesNo.PositionSequenceBinding Score1hsp105 180-188NYGIYKQDL24002hsp105 214-223AFNKGKLKVL9603hsp105 251-260KYKLDAKSKI28804hsp105 305-313QFEELCAEL13825hsp105 433-442TFLRRGPFEL19206hsp105 570-579MYIETEGKMI48007hsp105 597-606ECVYEFRDKL808hsp105 682-690HYAKIAADF609hsp105 696-705KYNHIDESEM432

example 3

[0095] Plasmid DNA produced by incorporating mouse hsp105 cDNA into an expression vector pCAGGS was adjusted to be a suitable concentration. It was then used as a vaccine for the following performance evaluation test. With regard to this mouse hsp105-pCAGGS DNA vaccine, Escherichia coli was cultured, and thereafter, plasmid DNA was extracted from the Escherichia coli and purified, so as to produce the vaccine in large scale.

[0096] The following samples were injected into the muscle of each BALB / c mouse: (1) a normal saline solution, (2) only a vector, (3) a hsp105 cDNA vector, (4) only an adjuvant, (5) an adjuvant +a peptide. Thereafter, a colon cancer cell line Colon-26 derived from a syngeneic mouse, that highly expresses hsp105, was subcutaneously transplanted into the back of the mouse. Thereafter, the development of the cancer in the mice was evaluated in the following points: (1) the area of a cancerous portion, (2) the ratio of mice in which the cancer developed, and (3) the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.

Description

TECHNICAL FIELD [0001] The present invention relates to a novel human cancer antigen that is useful for diagnosis of various types of cancers such as pancreatic cancer or colon cancer and for immunotherapy, and use thereof. BACKGROUND ART [0002] At present, cancer is the number one cause of death. Occurrence mechanisms, diagnostic methods, and therapeutic methods for cancer have been developed. However, a large number of advanced cancers have not yet been treated under the present circumstances. In order to improve the current situation, it is considered to be necessary to develop a novel early diagnostic method and therapeutic method. [0003] Immunotherapy has long been anticipated as a method for treating cancers, and various attempts have been made regarding such therapy. However, sufficient antitumor effects have not yet been exhibited. Conventionally, immunotherapy for cancers had previously been centered on nonspecific immunotherapy. In recent years, however, it has been clarif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00C12Q1/68G01N33/574C07H21/04C12P21/06C12N5/08C07K14/82A61P35/00C07K14/47
CPCA61K39/00G01N33/57438G01N33/57419C07K14/4748A61P1/04A61P1/16A61P1/18A61P11/00A61P13/08A61P13/10A61P13/12A61P15/00A61P17/00A61P25/00A61P35/00A61P35/02A61P35/04A61P37/04A61P43/00A61P5/14
Inventor NAKATSURA, TETSUYANISHIMURA, YASUHARU
Owner MEDINET CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap